| Ticker Details |
ABBVIE INC.
AbbVie Inc is a biopharmaceutical company that discovers, develops, manufactures and sells a range of pharmaceutical products for treating chronic autoimmune diseases, virology and neurological disorders.
|
| IPO Date: |
December 14, 2012 |
| Sector: |
Healthcare |
| Industry: |
Drug Manufacturers |
| Market Cap: |
$375.69B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.06 | 1.02%
|
| Avg Daily Range (30 D): |
$2.59 | 1.19%
|
| Avg Daily Range (90 D): |
$2.49 | 1.13%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
6.2M |
| Avg Daily Volume (30 D): |
4.66M |
| Avg Daily Volume (90 D): |
4.54M |
| Trade Size |
| Avg Trade Size (Sh.): |
103 |
| Avg Trade Size (Sh.) (30 D): |
51 |
| Avg Trade Size (Sh.) (90 D): |
52 |
| Institutional Trades |
| Total Institutional Trades: |
64,269 |
| Avg Institutional Trade: |
$10.64M |
| Avg Institutional Trade (30 D): |
$31.66M |
| Avg Institutional Trade (90 D): |
$29.53M |
| Avg Institutional Trade Volume: |
.1M |
| Avg Institutional Trades (Per Day): |
19 |
| Market Closing Trades |
| Avg Closing Trade: |
$92.22M |
| Avg Closing Trade (30 D): |
$366.44M |
| Avg Closing Trade (90 D): |
$313.29M |
| Avg Closing Volume: |
787.16K |
|
|
| Financials |
| |
TTM |
Q4 2025 |
FY 2025 |
|
Basic EPS
|
$2.37
|
$1.02
|
$2.37
|
|
Diluted EPS
|
$2.36
|
$1.02
|
$2.36
|
|
Revenue
|
$61.16B
|
$16.62B
|
$61.16B
|
|
Gross Profit
|
$42.96B
|
$12.07B
|
$42.96B
|
|
Net Income / Loss
|
$4.23B
|
$1.82B
|
$4.23B
|
|
Operating Income / Loss
|
$15.08B
|
$4.54B
|
$15.08B
|
|
Cost of Revenue
|
$18.2B
|
$4.55B
|
$18.2B
|
|
Net Cash Flow
|
$-295M
|
$-400M
|
$-295M
|
|
PE Ratio
|
88.11
|
|
|
|
|
|
